Trial ID or NCT#

NCT01844986

Status

not recruiting iconNOT RECRUITING

Purpose

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.

Official Title

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Eligibility Criteria

Ages Eligible for Study: 18 Years to 130 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No

Investigator(s)

Oliver Dorigo, M.D., Ph.D.
Oliver Dorigo, M.D., Ph.D.
Gynecologic oncologist, Medical oncologist, Gynecologic oncologist
Associate Professor of Obstetrics and Gynecology (Oncology)
Nelson Teng
Jonathan S. Berek, MD, MMSc
Jonathan S. Berek, MD, MMSc
Gynecologic oncologist
Laurie Kraus Lacob Professor
Amer Karam
Amer Karam
Gynecologic oncologist, Medical oncologist, Obstetrician and Gynecologist (OB-GYN)
Clinical Professor, Obstetrics & Gynecology - Gynecologic Oncology

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061